Skip to content
HowShorted

Phathom Pharmaceuticals, Inc. short interest in 2026

In 2026, Phathom Pharmaceuticals, Inc.'s disclosed short interest ran from 14.79% of shares outstanding on 15 Jan 2026 to 12.56% on 15 Sep 2026, a change of -2.23 percentage points. The year's high was 16.47% on 13 Feb 2026 and its low 12.21% on 30 Apr 2026, averaging 14.53% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.85 days on 13 Feb 2026. Full history: Phathom Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Phathom Pharmaceuticals, Inc. in 2026

2026 in figures

Start of year
14.79% (15 Jan 2026)
End of year
12.56% (15 Sep 2026)
Change
-2.23 pp
High
16.47% (13 Feb 2026)
Low
12.21% (30 Apr 2026)
Average
14.53%
Highest days to cover
14.85 (13 Feb 2026)
SEC filings marked
7

Every report in 2026

Phathom Pharmaceuticals, Inc. short interest in 2026
SettlementShort interestDays to coverFilings since previous
15 Jan 202614.79%6.48results (8-K)
30 Jan 202616.02%10.88
13 Feb 202616.47%14.85
27 Feb 202615.70%9.8110-K filed, results (8-K)
13 Mar 202616.39%10.93
31 Mar 202614.95%9.23
15 Apr 202613.36%9.92
30 Apr 202612.21%5.8810-Q filed, results (8-K)
15 May 202612.90%8.68
29 May 202612.98%9.41
15 Jun 202614.00%10.36
30 Jun 202615.04%11.67
15 Jul 202615.20%9.00
31 Jul 202616.47%8.7010-Q filed, results (8-K)
14 Aug 202614.55%6.87
31 Aug 202613.38%11.01
15 Sep 202612.56%9.11

See also: Phathom Pharmaceuticals, Inc.'s full history · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.